ADIENNE Pharma & Biotech

adienne.com

ADIENNE is an integrated biopharmaceutical group of companies with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

news image

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

Read More

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

news image

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More

Medical

JNANA THERAPEUTICS ANNOUNCES POSITIVE CLINICAL PROOF OF CONCEPT ACHIEVED WITH JNT-517, A POTENTIAL FIRST-IN-CLASS ORAL TREATMENT FOR PKU

Jnana Therapeutics, Inc. | February 02, 2024

news image

Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all age...

Read More

Cell and Gene Therapy

CERES NANOSCIENCES AND GINKGO BIOWORKS PARTNER TO BRING PATHOGEN MONITORING CAPABILITIES TO LABS AROUND THE WORLD

prnewswire | September 14, 2023

news image

Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, inclu...

Read More
news image

Industrial Impact

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

Read More
news image

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More
news image

Medical

JNANA THERAPEUTICS ANNOUNCES POSITIVE CLINICAL PROOF OF CONCEPT ACHIEVED WITH JNT-517, A POTENTIAL FIRST-IN-CLASS ORAL TREATMENT FOR PKU

Jnana Therapeutics, Inc. | February 02, 2024

Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all age...

Read More
news image

Cell and Gene Therapy

CERES NANOSCIENCES AND GINKGO BIOWORKS PARTNER TO BRING PATHOGEN MONITORING CAPABILITIES TO LABS AROUND THE WORLD

prnewswire | September 14, 2023

Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, inclu...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us